The Global Lacrimal Devices Market accounted for US$ 137 Mn in 2020 and is expected to reach US$ 185 Mn by 2028 with a considerable CAGR of 3.9% during the forecast timeframe of 2021 to 2028.
A disorder of the tear drainage system can lead to excessive accumulation of tears in the eye, causing the eyes to constantly water and become irritated. In addition, blockages in the tear ducts can lead to recurring painful infections that require antibiotic drops and tablets to treat. This can negatively impact vision and overall quality of life. On the other hand, lacrimal devices are an eye protection system that helps keep watery eyes free from dust and dirt. Additionally, lacrimal duct devices such as stents and intubation devices have been used in the past to stem the tear processes from patency following trauma, surgery, reconstruction, and other procedures. It has recently been highlighted for its physiological role in the full function of the epiphora. In addition, dry eye is a complicated condition that is among the most common in the world. The lack of hydrophilic tears, which are mainly secreted by the lacrimal gland, is one of the main causes of dry eye. However, the lacrimal gland is essential to maintaining the health of the surface of the eye and protecting it from environmental stressors.
• Growing cases of eye problems
• Innovations in lacrimal device technology
• Alternative therapies available for epiphora health issues
• High risk of adverse effects
• Advantages associated with lacrimal stents
• Rising cases of glaucoma disease
|Market||Lacrimal Devices Market|
|Market Size 2021||US$ 137 Mn|
|Market Forecast 2028||US$ 185 Mn|
|CAGR||3.9% During 2021 - 2028|
|Analysis Period||2018 - 2030|
|Forecast Data||2021 - 2028|
|Segments Covered||By Product, By Application, By End-Use And By Geography
|Regional Scope||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa|
|Key Companies Profiled||BVI Medical, Bess Medical Technology GmbH, FCI Ophthalmic, Aurolab, Gunther Weiss Scientific, Kaneka Corporation, Lacrimedics, Rumex International, Cook Medical LLC, and Sinopsys Surgical, Inc.|
||Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis|
10 hrs of free customization and expert consultation
Lacrimal Devices Market Dynamics
Factors such as an increase in the number of patients with obstruction of the nasolacrimal duct and growing demand for ophthalmic therapies with a higher success rate and rarer interventions are primarily driving the lacrimal device market. Additionally, technological developments, the launch of new products and components, and a growing preference for opticians are expected to drive the market globally. However, the benefits of tear irrigation and treatment procedures, along with the impressive results achieved through the use of low-cost tear devices, are expected to provide significant market growth opportunities during the forecast period. Furthermore, the availability of alternative treatments for epiphora health conditions is a major restraint on the lacrimal stent industry. Additionally, most pharmaceutical companies are currently interested in developing promising drugs to treat eye diseases, which is hampering the growth of the lacrimal device industry.
Market by Product
By product, the stent segment accounted for more than 25% of revenue share in 2020. A lacrimal stent is a bicanalicular intubation device used to intubate the tear drainage apparatus, particularly in cases of dacryocystorhinostomy. In the past, various materials such as synthetic, organic, and metallic materials have been used as stents for puncta or stenotic tubules. However, Graue described the first-ever stent use in 1932. Since then, materials such as nylon, silk, dacron, and polypropylene have been used and their designs have evolved to improve retention and minimize collateral damage. Recently, newer stents have further improved success rates and reduced the risk of complications.
Market by Application
Based on the application, the dry eyes segment accounted for significant market shares during the forecasting timeframes. Dry eyes are a considerable global problem that affects over 344 million people worldwide, including over 30 million in the United States alone. A dry eye did occur when there aren't enough tears to keep eyes properly nourished and lubricated. Dry eyes symptoms are caused by aging, autoimmune disease; hormonal changes, inflamed eyelid glands or allergens eye disease, and also adverse reactions to certain medications, such as antihistamines. Moreover, dry eye can also be caused by drying out from the tear film in addition to a disparity in the lacrimal system of the eye. This can be made worse by dry air produced by air conditioning, heat, or other environmental factors.
Market by End-Use
Based on the end-use, the hospital was the dominantsegment in 2020. The hospital segment is driving the global lacrimal device market due to presence of advanced infrastructure, well-trained qualified staff, and the availability of modern equipment and technological devices. Furthermore, the increasing number of hospital visits, the rising prevalence of eye problems, the growing number of patients undergoing surgical procedures, and the availability of reimbursements for these treatments are driving the segment's growth.
Lacrimal Devices Market Regional Overview
Middle East & Africa
North America dominates the global lacrimal devices market due to the region's high acceptance rate of lacrimal equipment, well-established healthcare sector, and increased incidence of eye diseases. The United States has the largest market share in the North American region, owing to better surgical device regulations and a growing public awareness of the need for such procedures in cases of lacrimal duct obstruction. However, in the United States alone, about 12 million people over the age of 40 suffer from eye diseases, of which about 1 million are blind. Furthermore, the growing elderly population citizenry and the presence of major players are expected to drive market growth during the forecasted periods.
Some of the prominent players in global lacrimal devicesmarket are BVI Medical, Bess Medical Technology GmbH, FCI Ophthalmic, Aurolab, Gunther Weiss Scientific, Kaneka Corporation, Lacrimedics, Rumex International, Cook Medical LLC, and Sinopsys Surgical, Inc.
The estimated value of global lacrimal devicesmarketin 2020 was accounted to be US$137Mn.
The projected CAGR of lacrimal devices during the analysis period of 2021 to 2028 is 3.9%.
The prominent players of the global lacrimal devices market involve FCI Ophthalmic, Aurolab, Kaneka Corporation, BVI Medical, Gunther Weiss Scientific, Lacrimedics, Rumex International, Cook Medical LLC, Sinopsys Surgical, Inc. and Bess Medical Technology GmbH.
North America held the dominating share for lacrimal devices during the analysis period of 2021 to 2028
Asia-Pacific region exhibited fastest growing CAGR for lacrimal devices during the analysis period of 2021 to 2028
Growing prevalence of eye disease as well as technological advancements in lacrimal devices are the prominent factors that fuel the growth of global lacrimal devices market
Based on product, stents segment held the maximum share for lacrimal devices market in 2020